Vitronectin Concentrations Predict Risk in Patients Undergoing Coronary Stenting
Vitronectin Concentrations Predict Risk in Patients Undergoing Coronary Stenting
复制标题
DOI：
10.1161/circinterventions.108.795799
复制
发表时间：
2009-02-01
影响因子：
5.6
通讯作者：
Dechend, Ralf
中科院分区：
文献类型：
--
作者：
Derer, Wolfgang;Barnathan, Elliot S.;Dechend, Ralf
背景-玻连蛋白是一种多功能蛋白质，具有与多种血浆和细胞蛋白相互作用的多个结合结构域。玻连蛋白结合多种配体，包括可溶性玻连蛋白受体。阿昔单抗与可溶性玻连蛋白受体和糖蛋白IIb/IIIa的结合同样良好，因为两者都具有β（3）亚基。我们测试了玻连蛋白浓度是否与急性冠脉综合征患者的不良结局相关。方法和结果：回顾性分析了阿昔单抗加支架植入（血小板IIb/IIIa抑制剂支架植入EPISTENT的评价）的随机、安慰剂对照试验的基线血清样本（n=233）。我们将玻连蛋白浓度分为3个较低的四分位数（n=178; = 49.7 μ g/mL）。研究终点为30天和6个月时的主要心血管不良事件，定义为死亡、心肌梗死或紧急血运重建。具有基线玻连蛋白的患者比例较高
Background-Vitronectin is a multifunctional protein with a multiple binding domain that interacts with a variety of plasma and cell proteins. Vitronectin binds multiple ligands, including the soluble vitronectin receptor. Abciximab binds equally well to soluble vitronectin receptor and glycoprotein IIb/IIIa, because both share the beta(3) subunit. We tested whether vitronectin concentrations correlate with adverse outcomes in acute coronary syndrome patients.Methods and Results-Baseline serum samples (n=233) from a randomized, placebo-controlled trial of abciximab plus stenting (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting EPISTENT) were retrospectively analyzed. We stratified vitronectin concentrations into the 3 lower quartiles (n=178; = 49.7 mu g/mL). The end point was a major adverse cardiovascular event defined as death, myocardial infarction or urgent revascularization at 30 days and 6 months. A higher proportion of patients with baseline vitronectin